Real-World Use of Loteprednol Etabonate 0.5%/Tobramycin 0.3% Ophthalmic Suspension for the Treatment of Ocular Surface Inflammatory Conditions

Deom JE, Kannarr S, Vollmer P

Clinical Ophthalmology 2022, 16:3803-3809

Published Date: 17 November 2022